Even though customers may only buy certain OTC categories a few times a year, for consumer healthcare brands, the opportunities to have a more meaningful relationship in the lives of their consumers has never been greater, Stefan Merlo, director of healthcare strategy, Novartis Consumer Health, told DSNtv in a special edition of DSN Executive Viewpoints.
More Americans are more often seeking their ounce of prevention. According to Bain & Co.’s recent Healthy Living Survey, 75% of consumers are in pursuit of a healthier lifestyle. Take that predominant mindset, coupled with the outcomes-driven preventive focus associated with the Affordable Care Act, and you have a formula for OTC success at retail pharmacy.
The January/February 2014 Vitamins and Supplements Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Vitamints Immune, Centrum Specialist Immune Support, Alive! Children's Multi-Vitamin Gummy, Natrol's Melatonin, VitaMelts Multi, TruBiotics, Align and Culturelle Digestive Health Capsules.
The November/December 2013 Cough, Cold and Flu Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Robitussin Maximum Strength, NyQuil Severe Cold & Flu, Theraflu Warming Caplets, Coricidin HBP Cold & Flu, Tylenol Cold & Flu Severe, Hyland's Defend Severe Cold & Flu, Similasan Mucus Relief and Splintek Night Guard.
Such iconic pain relief brands as McNeil Consumer’s Tylenol and Motrin, and Novartis’ Excedrin, have made their way back to the shelf this fall following a recall-driven hiatus. And the sales have already started to accumulate.
The September/October 2013 Digestive Aids Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Tums Chewy Delights, Alka Seltzer Fruit Chews, Maximum Strength Zantac 150 Cool Mint, Maximum Strength Pepcid AC, Prilosec OTC (Wildberry Flavor), Prevacid 24 Hour, Zegerid OTC and Gas-X.
Both Novartis Consumer Health and McNeil Consumer Healthcare will be making strong comebacks across their respective analgesic portfolios in the second half of this year, which will make a fourth-quarter battle royale across analgesics, as well as cough-cold.
The July/August 2013 Pain Relief Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Tylenol 8 Hour, Advil Liqui-Gels, Aleve Liquid Gels, Bayer Aspirin Plus, Excedrin Extra Strength, Hyland's Leg Cramps, BenGay Pain Relief and Massage, and Salonpas Pain Relief Patch.
With private label across analgesics up an estimated 11.3% to $1.7 billion, retailers are going to need to make some tough decisions as two internal analgesic powerhouses — McNeil's Tylenol and Novartis' Excedrin — make their way back onto market after respective recalls.
Progress at re-opening its manufacturing facility in Lincoln, Neb., has been slow-going, Novartis reported Thursday, but the company has contracted third-party manufacturers to resume production of Excedrin, Lamisil and Triaminic.
Bayer HealthCare's Consumer Care Division on Tuesday introduced Bayer Migraine Formula, an over-the-counter medication designed to relieve migraine pain and accompanying symptoms like nausea, phonophobia (sound sensitivity) and photophobia (light sensitivity) through a formulation of aspirin, acetaminophen and caffeine.
The U.S. over-the-counter drug market saw strong growth in 2011, thanks to switches of prescription drugs to OTC, gains in the allergy relief products category and holistic marketing, according to a new report from Kline.
The National Advertising Review Board on Tuesday recommended that Novartis Consumer Health discontinue advertising claims that the company’s Excedrin Extra Strength product starts relieving headache pain faster than Advil.
McNeil Consumer Healthcare on Thursday announced plans for new dosing instructions, lowering the maximum daily dose for single-ingredient Extra Strength Tylenol (acetaminophen) products sold in the United States from eight pills per day (4,000 mg) to six pills per day (3,000 mg).
Product recalls over the past two years have eroded consumer trust in over-the-counter drugs; however, those same recalls represent opportunity for smaller market players to gain exposure and build brand awareness, wrote Laura Mahecha, industry manager for health care at research firm Kline, in an online report issued Wednesday.